SCHEMBL2813446

SCHEMBL2813446

COC(=O)c1ccc2cccc(OS(=O)(=O)C(F)(F)F)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.44
NOTUM Q6P988 2/20 0.42
PLA2G2D Q9UNK4 1/20 0.41
SDHB P21912 1/20 0.41
PTPN11 Q06124 1/20 0.40
POLB P06746 1/20 0.40
LCK P06239 1/20 0.40
TRPV1 Q8NER1 2/20 0.40
TP53 P04637 1/20 0.39
HTT P42858 2/20 0.39
ALOX15 P16050 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
PFKFB3 Q16875 1/20 0.39
PFKFB4 Q16877 1/20 0.39
PDK2 Q15119 2/20 0.38
PLAU P00749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16509489 0.90 PDK2 (0.42) NQO2NOTUMPLA2G2DSDHBPTPN11
SCHEMBL16509512 0.86 NOTUM (0.38) NQO2NOTUMPLA2G2DSDHBPTPN11
SCHEMBL18198419 0.85 NOTUM (0.42) NQO2NOTUMSDHBPTPN11LCK
SCHEMBL4893119 0.83 NOTUM (0.41) NQO2NOTUMSDHBLCKTP53
SCHEMBL7214605 0.82 KDM4E (0.49) SDHBKDM4EALDH1A1HPGDPDK2
SCHEMBL3095236 0.81 GRIN2D (0.45) POLBKDM4EALDH1A1GAAHPGD
SCHEMBL16502686 0.80 NOTUM (0.45) NOTUMLCKHTTKDM4EPDK2
SCHEMBL16502437 0.80 NOTUM (0.42) NQO2NOTUMSDHBPTPN11LCK
SCHEMBL10030428 0.80 NOTUM (0.48) NQO2NOTUMLCKTP53HTT
SCHEMBL124046 0.79 MTNR1A (0.47) NQO2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
EP-2394987-A1 ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-14 EP disclosed
US-20100249179-A1 Farnesoid X Receptor Agonists SMITHKLINE BEECHAM CORPORATION (US) 2010-09-30 US disclosed
US-20100249179-A1 Farnesoid X Receptor Agonists SMITHKLINE BEECHAM CORPORATION (US) 2010-09-30 US disclosed
US-20100249179-A1 Farnesoid X Receptor Agonists SMITHKLINE BEECHAM CORPORATION (US) 2010-09-30 US disclosed
EP-2170072-A1 FARNESOID X RECEPTOR AGONISTS GlaxoSmithKline LLC (US) 2010-04-07 EP disclosed
WO-2008157270-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
WO-2008157270-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES HTR5A, HTR2A, HTR1A NQO2 641/4885NOTUM 1199/4885PLA2G2D 841/4885
US-20100249179-A1 Farnesoid X Receptor Agonists NR1H4, NR1H3, NR1H2 NQO2 2742/4885NOTUM 2201/4885PLA2G2D 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.